Seaport Therapeutics Director Denice Torres Buys $99.3K of Stock
Denice Torres, Director, bought 5,000 shares of Seaport Therapeutics, Inc. at $19.86 a share, worth $99.3K in total on Nov 3, 2026. Shares held after the trade: 5,000.
Seaport Therapeutics is a clinical-stage therapeutics company that recently transitioned to public markets, reporting 53,530,550 shares of voting common stock outstanding as of October 2026. The filing indicates the company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company, focusing on advancing its clinical pipeline and research programs.
Seaport Therapeutics reported third quarter 2026 financial results, ending the period with $403.8 million in cash and investments. The company highlighted clinical progress, including the dosing of the first patient in a Phase 2a trial for GlyphAgo and positive Phase 1 driving simulation data for GlyphAllo. Management expects current capital to fund operations into 2029, covering three upcoming mid-to-late-stage clinical data readouts.
“Over the last few months, Seaport met two key clinical milestones – we dosed the first patient in the Phase 2a proof-of-pharmacology trial of GlyphAgo in patients with GAD and sleep disturbance, and demonstrated that GlyphAllo did not impair next-morning driving performance in a Phase 1 driving trial.”
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
“Seaport is well-capitalized, with cash runway through all three of our upcoming mid-to-late-stage clinical data readouts. There are a billion people living with mental illness – waiting and hoping for better medicines. We are committed to our mission to bring better days to patients and their families.”
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics